{
    "nctId": "NCT03529565",
    "briefTitle": "Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone",
    "officialTitle": "The Role of Histamine in Breast Cancer Bone Pain",
    "overallStatus": "TERMINATED",
    "conditions": "Bone Pain, Breast Carcinoma Metastatic in the Bone",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 17,
    "primaryOutcomeMeasure": "Plasma histamine levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer patients with radiographic evidence of bone metastases (by plain film, computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], positron emission tomography \\[PET\\] or bone scan) within 8 weeks of registration\n\n  * Weight bearing sites: pelvis (excluding pubis), femur, sacrum and/or sacroiliac joints, tibia, up to 5 consecutive cervical, thoracic or lumbar vertebral bodies, lumbosacral spine\n  * Non-weight bearing sites: up to 3 consecutive ribs, humerus, fibula, radius +/- ulna, clavicle, sternum, scapula, pubis\n* Patients with and without pain related to the radiographically documented metastases are eligible for study\n* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document\n\nExclusion Criteria:\n\n* Pregnant women will be excluded",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}